Biogen Securities Litigation

Share

In a 10b-5 trial in the U.S. District Court in Boston that was closely watched by corporate counsel across the country, Cornerstone Research assisted counsel in their defense of Biogen, Inc.

Retained by Mintz Levin Cohn Ferris Glovsky and Popeo

In a 10b-5 trial in the U.S. District Court in Boston that was closely watched by corporate counsel across the country, Cornerstone Research assisted counsel in their defense of Biogen, Inc. The plaintiffs alleged that Biogen had misrepresented Phase III results for a new drug. Professor Christopher James of the University of Florida testified on behalf of the defense, analyzing stock price movements related to the Phase III announcements and successfully rebutting plaintiffs’ causation arguments. The plaintiffs’ expert claimed $68 million in damages; the jury found no liability and no damages.

Case Expert

Christopher M. James

William H. Dial/SunBank Eminent Scholar in Finance and Economics,
Warrington College of Business Administration,
University of Florida;
Senior Advisor, Cornerstone Research